KT

Kalaris Therapeutics Inc

KLRS·NASDAQ

$4.70

-0.42%
HealthcareBiotechnology

Kalaris Therapeutics Inc operates as a pharmaceutical company. The Company specializes in the development of novel cell therapies with a focus on restoring natural immunity against life-threatening virus-associated diseases in patients with severely weakened immune systems.

At a Glance

Live Snapshot
Market Cap$87.90M
EPS-2.8500
P/E Ratio-1.65
Earnings Date08/12/2026

klrs

Sales/Maturities of Investments

Last Annual Value

15.00M

3-Year CAGR

%

5-Year CAGR

-35%

10-Year CAGR

-19%

KT

Kalaris Therapeutics Inc Competitors Analysis of Sales/Maturities of Investments

KLRS · NASDAQ
CompanySales/Maturities of Investments
CAGR 3Y
CAGR 5Y
CAGR 10Y
15.00M
N/A-43.6%N/A 
42.00M
-29.5%N/AN/A
110.87M
60.5%N/AN/A
35.60M
-42.9%-29.3%N/A
0.00
N/AN/AN/A
167.47M
-14.0%N/AN/A
60.40M
-23.4%-34.5%4.8%
134.39M
-22.8%N/AN/A
0.00
N/AN/AN/A
0.00
N/AN/AN/A
96.88M
-6.4%26.1%20.5%
KT

Kalaris Therapeutics Inc Fair Value Envelope

KLRS · NASDAQ

Our analysis suggests that KLRS has a fair value of HIDDEN per share in the Base Case projection. With shares currently trading at $4.7, this represents a potential HIDDEN relative to our calculated worth for Kalaris Therapeutics Inc.

Intrinsic Value
Current Price: $4.7